Polymorphic fingerprint as an approach to authenticate Iberian pig categories

High-commercial-value products are often susceptible to food fraud. Among them, Iberian dry-cured ham is highly appreciated due to its particular and sensory, but also nutritional, properties. There are four different Iberian ham categories (namely bellota, recebo, cebo de campo and cebo), which directly depend on the rearing system of the pig during the last stage of the fattening phase. However, there is still a lack of a normalized and robust method capable of authenticating the different product categories and, therefore, preventing mislabeling. In the present work, we characterized the polymorphic behavior of raw (before curing) lipid extracts belonging to the four categories of Iberian pig. A total of 80 different samples were analyzed by DSC, and synchrotron radiation XRD experiments were carried out for selected ones. The results obtained showed that bellota and recebo categories exhibited essentially the same crystallization and polymorphic behavior and this was significantly different (p < 0.05) from that of cebo de campo and cebo. The latter exhibited higher crystallization and melting temperatures than bellota and recebo samples, due to the occurrence of an additional β′-2L polymorphic form. By considering the differences in rearing systems of pigs belonging to the different categories, we concluded that the key factor which determined the polymorphism of Iberian pig lipid extracts was not the physical exercise practiced by the pig, but the inclusion of acorns in the feeding system. This work demonstrated that thermal and crystallographic techniques, like DSC and XRD, may be promoted to be used as fingerprinting tools for the authentication of high-value food products

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patientsThis work was sponsored by GEICAM and Novartis. Roche funded the publication fees for this articl

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

<p>Abstract</p> <p>Background</p> <p>Aromatase (<it>CYP19A1</it>) regulates estrogen biosynthesis. Polymorphisms in <it>CYP19A1 </it>have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of <it>CYP19A1 </it>and their effect on response to neoadjuvant letrozole in early BC.</p> <p>Methods</p> <p>We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4^thmonth by World Health Organization (WHO) criteria. Three polymorphisms of <it>CYP19A1</it>, one in exon 7 (rs700519) and two in the 3'-UTR region (rs10046 and rs4646) were evaluated on DNA obtained from peripheral blood.</p> <p>Results</p> <p>Thirty-five women (36.8%) achieved a radiological response to letrozole. The histopathological and immunohistochemical parameters, including hormonal receptor status, were not associated with the response to letrozole. Only the genetic variants (AC/AA) of the rs4646 polymorphism were associated with poor response to letrozole (p = 0.03). Eighteen patients (18.9%) reported a progression of the disease. Those patients carrying the genetic variants (AC/AA) of rs4646 presented a lower progression-free survival than the patients homozygous for the reference variant (p = 0.0686). This effect was especially significant in the group of elderly patients not operated after letrozole induction (p = 0.009).</p> <p>Conclusions</p> <p>Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.</p

Obtención de la aleación NiTi para aplicaciones dentales

Por sus características la aleación Ni-Ti podría usarse en prótesis dental. Se describen sus propiedades novedosas en el campo de la odontología restauradora como son la pseudoelasticidad que proporciona grandes deformaciones elásticas y el efecto de memoria de forma que le confiere la capacidad de recuperar la forma mediante cambios términos. Se expone la obtención de una aleación cuya composición química y proceso de fabricación, riguroso y complejo, determinan que el paso de la fase martensitica a la fase austenitica se realice entre temperaturas biocompatibles con los tejidos de la boca. Y por último se describe el proceso de colado de dicha aleación con la técnica de la cera perdida, normalmente usada en los laboratorios de prótesis dental